JP2025512366A - 固形がんを処置するための組成物および方法 - Google Patents

固形がんを処置するための組成物および方法 Download PDF

Info

Publication number
JP2025512366A
JP2025512366A JP2024560262A JP2024560262A JP2025512366A JP 2025512366 A JP2025512366 A JP 2025512366A JP 2024560262 A JP2024560262 A JP 2024560262A JP 2024560262 A JP2024560262 A JP 2024560262A JP 2025512366 A JP2025512366 A JP 2025512366A
Authority
JP
Japan
Prior art keywords
cancer
composition
bladder
glycine
myeloperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512366A5 (https=
Inventor
ロバート シー． アレン，
ジャクソン ティー． ジュニア スティーブンス，
Original Assignee
エクソゼミス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクソゼミス，インコーポレイテッド filed Critical エクソゼミス，インコーポレイテッド
Publication of JP2025512366A publication Critical patent/JP2025512366A/ja
Publication of JP2025512366A5 publication Critical patent/JP2025512366A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024560262A 2022-04-13 2023-04-12 固形がんを処置するための組成物および方法 Pending JP2025512366A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330553P 2022-04-13 2022-04-13
US63/330,553 2022-04-13
PCT/US2023/018289 WO2023200842A1 (en) 2022-04-13 2023-04-12 Compositions and methods for treating solid cancer

Publications (2)

Publication Number Publication Date
JP2025512366A true JP2025512366A (ja) 2025-04-17
JP2025512366A5 JP2025512366A5 (https=) 2026-03-30

Family

ID=88330172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560262A Pending JP2025512366A (ja) 2022-04-13 2023-04-12 固形がんを処置するための組成物および方法

Country Status (10)

Country Link
US (1) US20250332226A1 (https=)
EP (1) EP4507793A1 (https=)
JP (1) JP2025512366A (https=)
KR (1) KR20250004257A (https=)
CN (1) CN119677528A (https=)
AU (1) AU2023252830A1 (https=)
CA (1) CA3246603A1 (https=)
IL (1) IL316053A (https=)
MX (1) MX2024012316A (https=)
WO (1) WO2023200842A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
CA3196357A1 (en) * 2020-11-11 2022-05-19 Robert C. Allen Compositions and methods for treating solid cancer

Also Published As

Publication number Publication date
EP4507793A1 (en) 2025-02-19
AU2023252830A1 (en) 2024-10-10
IL316053A (en) 2024-11-01
WO2023200842A1 (en) 2023-10-19
CN119677528A (zh) 2025-03-21
KR20250004257A (ko) 2025-01-07
MX2024012316A (es) 2024-11-08
US20250332226A1 (en) 2025-10-30
CA3246603A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
EP0675727B1 (en) Glycolipid enzyme-polymer conjugates
US20100178273A1 (en) Methods and compositions for treating mucositis
CZ2003848A3 (cs) Způsob léčby poruch spojených s bcl-2 za použití antisense oligomerů bcl-2
CN103764137A (zh) 嗜伊红粒细胞过氧化物酶组合物和它们的使用方法
Stratford et al. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo
WO2010023195A2 (en) Compositions and methods for treating cancer
US5552390A (en) Phosphorothioate inhibitors of metastatic breast cancer
EP0062434B1 (en) Insoluble crosslinked cytotoxic oxidase-peroxidase system
Agostinelli et al. Hyperthermia enhances cytotoxicity of amine oxidase and spermine on drug-resistant LoVo colon adenocarcinoma cells
KR20230106646A (ko) 고형 암을 치료하기 위한 조성물 및 방법
JP2025512366A (ja) 固形がんを処置するための組成物および方法
JPH08283296A (ja) ヒトアポリポプロテインｅアナログ及びヒトスーパーオキシドジスムターゼアナログ
US5756091A (en) Method of treating tumour cells using catalase
US6984619B1 (en) Method for protection against tumor metastasis formation
Yang et al. Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury
JPH0653670B2 (ja) 化学療法剤の副作用低減化剤
HK40098212A (zh) 用於治疗实体癌的组合物和方法
WO2009149201A1 (en) Methods of treatment for pulmonary fibrosis
Nakamura et al. Preparation of enzymatically highly active pegylated-D-amino acid oxidase and its application to antitumor therapy
Skrzycki et al. Superoxide dismutase as a potential therapeutic agent
Hosokawa et al. Tumor progression accelerated by oxygen species and its chemoprevention
JP3569904B2 (ja) 臓器障害治療薬
CA2525672A1 (en) Use of peroxovanadium compounds as tumour cell growth suppressor
AU2016353539B2 (en) Proenzyme composition
Flohé Superoxide dismutase: Rationale of therapeutic use, established clinical effects, and perspectives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260319